Compare
Qiagen N.V. vs Moderna, Inc. vs Exelixis, Inc. vs Neurocrine Biosciences Inc
| Latest fiscal year | Qiagen N.V. QGEN | Moderna, Inc. MRNA | Exelixis, Inc. EXEL | Neurocrine Biosciences Inc NBIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-02 | 2025-12-31 |
| Revenue | $2.09B | $1.94B | $2.32B | $2.86B |
| Revenue growth (YoY) | +5.7% | -39.9% | +7.0% | +21.4% |
| Gross margin | 62.2% | 55.3% (computed) | n/a | n/a |
| Operating margin | 22.3% | -158.1% | 37.6% | 21.6% |
| Net margin | 20.3% | -145.2% | 33.7% | 16.7% |
| Net income | $424.88M | -$2.82B | $782.57M | $478.60M |
| EPS (Diluted) | $1.94 | -$7.26 | $2.78 | $4.67 |
| Operating cash flow | $654.33M | -$1.87B | $884.27M | $782.70M |
| Free cash flow | $453.28M | -$2.06B | $875.84M | $748.70M |
| Cash & equivalents | $839.00M | $2.60B | $482.49M | $713.00M |
| Total assets | $6.28B | $12.34B | $2.84B | $4.63B |
| Total liabilities | n/a | $3.69B | $683.10M | $1.38B |
| Shareholders' equity | $3.78B | $8.65B | $2.16B | $3.25B |
| Return on year-end equity | 11.2% | -32.6% | 36.2% | 14.7% |
| Shares outstanding | n/a | 394.00M | 262.48M | 100.10M |
Revenue, most recent five fiscal years
| Fiscal year | Qiagen N.V. | Moderna, Inc. | Exelixis, Inc. | Neurocrine Biosciences Inc |
|---|---|---|---|---|
| Latest | $2.09B Ended 2025-12-31 | $1.94B Ended 2025-12-31 | $2.32B Ended 2026-01-02 | $2.86B Ended 2025-12-31 |
| 1 year earlier | $1.98B Ended 2024-12-31 | $3.24B Ended 2024-12-31 | $2.17B Ended 2025-01-03 | $2.36B Ended 2024-12-31 |
| 2 years earlier | $1.97B Ended 2023-12-31 | $6.85B Ended 2023-12-31 | $1.83B Ended 2023-12-29 | $1.89B Ended 2023-12-31 |
| 3 years earlier | $2.14B Ended 2022-12-31 | $19.26B Ended 2022-12-31 | $1.61B Ended 2022-12-30 | $1.49B Ended 2022-12-31 |
| 4 years earlier | $2.25B Ended 2021-12-31 | $18.47B Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $1.13B Ended 2021-12-31 |